Difference between revisions of "Invasive breast cancer"
Jump to navigation
Jump to search
(subdivide, re-arrange sections) |
(→Characteristics of the subtypes: +carcinoma) |
||
| Line 120: | Line 120: | ||
=Characteristics of the subtypes= | =Characteristics of the subtypes= | ||
==Ductal== | ==Ductal carcinoma== | ||
*[[AKA]] "NST" = No Specific Type. | *[[AKA]] "NST" = No Specific Type. | ||
| Line 131: | Line 131: | ||
*Typically: ER+, PR+, HER2-. | *Typically: ER+, PR+, HER2-. | ||
==Lobular== | ==Lobular carcinoma== | ||
===General=== | ===General=== | ||
*May be associated with a CDH-1 mutation.<ref>URL: [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33006 http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33006]. Accessed on: 19 April 2011.</ref> | *May be associated with a CDH-1 mutation.<ref>URL: [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33006 http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33006]. Accessed on: 19 April 2011.</ref> | ||
| Line 171: | Line 171: | ||
#No tubule formation. | #No tubule formation. | ||
==Tubular== | ==Tubular carcinoma== | ||
===General=== | ===General=== | ||
Epidemiology: | Epidemiology: | ||